StemCell Therapy

A perfect mix of quantitative & qualitative Agriculture Biotechnologymarket information highlighting developments, industry challenges that competitors are facing along with gaps and opportunities available and would trend in Agriculture Biotechnologymarket. The study bridges the historical data from 2014 to 2019 and estimated until 2025.

The Agriculture BiotechnologyMarket report also provides the market impact and new opportunities created due to the COVID19/CORONA Virus Catastrophe The total market is further divided by company, by country, and by application/types for the competitive landscape analysis. The report then estimates 2020-2025 market development trends of Agriculture BiotechnologyIndustry.

Downlaod Sample ToC to understand the CORONA Virus/COVID19 impact and be smart in redefining business strategies. https://inforgrowth.com/CovidImpact-Request/6319455/agriculture-biotechnology-market

The Top players are ADAMA Agricultural Solutions, Vilmorin, Bayer, Biocentury Transgene, Certis, Dow AgroSciences, Eurofins, Evogene, Global Bio-chem Technology, Syngenta, KWS Saat, Marina Biotech, Monsanto, .

Market Segmentation:

On the basis of the end users/applications, Transgenic crops market, Synthetic biology-enabled products market

Download Free Sample PDF along with few company profileshttps://inforgrowth.com/sample-request/6319455/agriculture-biotechnology-market

Be the first to knock the door showing the potential that Agriculture Biotechnologymarket is holding in it. Uncover the Gaps and Opportunities to derive the most relevant insights from our research document to gain market size.

A major chunk of this Global Agriculture BiotechnologyMarket research report is talking about some significant approaches for enhancing the performance of the companies. Marketing strategies and different channels have been listed here. Collectively, it gives more focus on changing rules, regulations, and policies of governments. It will help to both established and new startups of the market.

The study objectives of this report are:To analyze global Agriculture Biotechnologystatus, future forecast, growth opportunity, key market, and key players.To present the Agriculture Biotechnologydevelopment in the United States, Europe, and China.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by product type, market, and key regions.

Get Special Discount Up To 50%, https://inforgrowth.com/discount/6319455/agriculture-biotechnology-market

Major Points from Table of Contents

1 Agriculture Biotechnology Agriculture Biotechnology Market Overview2 Agriculture Biotechnology Market Competition by Manufacturers3 Production Capacity by Region4 Global Agriculture Biotechnology Market by Regions5 Production, Revenue, Price Trend by Type6 Global Agriculture Biotechnology Market Analysis by Application7 Company Profiles and Key Figures in Agriculture Biotechnology Business8 Agriculture Biotechnology Manufacturing Cost Analysis9 Marketing Channel, Distributors and Customers10 Market Dynamics11 Production and Supply Forecast12 Consumption and Demand Forecast13 Forecast by Type and by Application (2021-2026)14 Research Finding and Conclusion15 Methodology and Data Source.

ENQUIRE MORE ABOUT THIS REPORT AT https://inforgrowth.com/enquiry/6319455/agriculture-biotechnology-market

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:Address: 6400 Village Pkwy suite # 104, Dublin, CA 94568, USAContact Name: Rohan S.Email:[emailprotected]Phone: +1-909-329-2808UK: +44 (203) 743 1898Website: http://www.inforgrowth.com

Go here to see the original:
Agriculture Biotechnology Market 2020: Potential growth, attractive valuation make it is a long-term investment | Know the COVID19 Impact | Top...

Global Biotechnology Reagents Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, Regional and Country Level.

Biotechnology Reagents Market Size Covers Global Industry Analysis, Size, Share, CAGR, Trends, Forecast And Business Opportunity.

>>Need a PDF of the global market report? Visit: https://industrystatsreport.com/Request/Sample?ResearchPostId=12804&RequestType=Sample

Global Biotechnology Reagents Market is valued at USD 71.25 Billion in 2018 and expected to reach USD 121.06 Billion by 2025 with the CAGR of 7.86% over the forecast period.

Increasing prevalence of diseases such as hepatitis B with growing research and development expenditure bybiotechnologytherapeutics and rising number of biotechnology firms globally are expected to boost the market over the forecast period.

Biotechnology reagents are the substances or compounds used to detect or create an additional substance in order to provide a test reading. Hence, the biotechnologies are used in research fields of genetics, molecular biology, diagnosis, immunology, bioscience and in education. The various uses of biotechnology reagents are; fluorescent microscopy, DNA analysis, immuno phenotyping and cell cycle analysis. The biotechnology reagents industry depends on the growth of biotechnology instrumentation market. Biotechnology reagents market includes technologies such as IVD, PCR, transfection, gene expression and cell culture. The basis of technology market is section into analytical reagents and life science reagents. The Life science technologies include in vitro diagnostics, unit culture, polymerase chain reaction and analytical technologies includes flow cytometry, electrophoresis, mass spectrometry and chromatography. The healthcare biotechnology is usually to improve medicines due to the advantages and pieces of knowledge it provides such as understanding the genetic composition of the human species, foundational structure of hereditary diseases manipulation and repairing of damaged genes to cure diseases. As the researchers might see the engineering of a supercharged flu virus as a perfectly reasonable way to better understand and thus fight the flu, the public might see the drawbacks as equally obvious the virus could escape, or someone could weaponize the research and the advanced genetic tools that some are considering for mosquito control could have unforeseen effects, possibly leading to environmental damage. Although the risks of biotechnology have been fretted over for decades, the increasing pace of progress from low cost DNA sequencing to rapid gene synthesis to precision genome editing suggests biotechnology is entering a new realm of maturity regarding both beneficial relevance and more worrisome risks.

Global Biotechnology Reagents Market report is segmented on the basis of type, application, and by regional & country level. Based on type, global biotechnology reagents market is classified as the Life science and analytical. Based upon application, global biotechnology reagents are classified into protein synthesis and purification, gene expression, DNA and RNA analysis and drug testing.

The regions covered in this biotechnology reagents market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, market of biotechnology reagents is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Key Players for Global Biotechnology Reagents Market Report-

Some major key players for Global Biotechnology Reagents Market are Life Technologies, Bio-Rad, Thermo Fisher Scientific, Water Corporation, Sigma-Aldrich Agilent Technologies Inc., Beckman Coulter, Roche, Abbott and others.

Global Biotechnology Reagents Market Dynamics

The rapidly increasing use of biotechnology reagents in therapeutics, basic research and its commercialization are the major factors responsible for the growth of this market. According to the World Health Organization (WHO) in 2017, prevalence of hepatitis B estimated about 27 million people 10.5% of all people estimated to be living with hepatitis B were aware of their infection, while 4.5 million around 16.7% of the people diagnosed were on treatment. Hence, the rising prices of DNA sequencing is predictable to serve this sector as a high impact rendering growth is expected to encourage researchers and manufacturers to increase R&D initiatives targeted at understanding genetic variations and developing therapeutic solutions for chronic diseases with large global prevalence such as cardiovascular diseases, diabetes, and cancer. According to the World Health Organization (WHO) in 2015, the estimates that in 257 million people were living with chronic hepatitis B infection as surface antigen positive, the hepatitis B resulted in an estimated 887 000 deaths, mostly from cirrhosis and hepatocellular carcinoma is primary liver cancer. In addition, the high investments in R&D activities, growing biomedical research, increasing number of biotechnology firms and advancement in stem cell research have contributed to the growth of the biotechnology reagents market.

The biotechnology organizations such as the department of biotechnology (DBT) with government funded institutions and other autonomous organizations representing the biotechnology sector, promote funding to support R&D and innovative produce development endeavors. One of the major challenges faced by this market use of biotechnology reagents in the field of drug discovery is an emerging market where proteomics, DNA chips, combinatorial chemistry, and high throughput screening enjoy the spotlight. In addition, high price of biopharmaceuticals may likely to restrain the growth of the biotechnology reagents market. Moreover, increase in the number of biotechnology firms around the globe and increase in research and development expenditure by the biotechnology corporation can provide various opportunities for the further growth of the market. The technological advancements and new product launches in health care and life science industries to life science reagents are an integral part of any clinical diagnostic laboratory and pharmaceutical & biotechnology industry. The recent technological advancements in molecular biology, life sciences, and biotechnology has brought about drastic changes in various fields such as medical diagnostics, drug discovery, personalized medicines, forensic sciences, and clinical research & development of the biotechnology reagents market.

Global Biotechnology Reagents Market Regional Analysis

Geographically,North America dominates the global biotechnology reagents market & incurs the highest expenditure for global R&D. According to the World Health Organization (WHO) in 2018, the chronic diseases in the United States are about 133 million Americans 45% of the population have at least one chronic disease. In addition, rising ongoing research in biological sciences considerable investments by various biotechnology companies and the consistently increasing utilization of biotechnology reagents in the market due to the continuing research and outsourcing activities in the field of life science in this region are also supplementing the market growth.

TheAsia Pacific is expected to show a lucrative growth rate during the forecast period due to increasing research and outsourcing activities in life science field. However, the regionlarge population, presence of emerging economies such as China and India, large number of elderly individuals in Japan presents significant opportunities for global players in these countries. Adoption of technologically advanced products in Japan, China, South Korea, Malaysia, and Singapore are likely to fuel the growth of the life science reagents market in this region. Moreover, increased investment by leading pharmaceutical and biotechnology companies in India and China, and rapidly increasing number of hospitals and diagnostic laboratories in the region boost the growth of the biotechnology reagents market in the region.

Key Benefits for Global Biotechnology Reagents Market Report

Global market report covers in depth historical and forecast analysis.

Global market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.

Global market report helps to identify opportunities in market place.

Global market report covers extensive analysis of emerging trends and competitive landscape.

By Type

By Application

By Regional & Country Analysis

Need a PDF of the global market report? Visit: https://industrystatsreport.com/Request/Sample?ResearchPostId=12804&RequestType=Methodology

Table of Content:

Market Overview: The report begins with this section where product overview and highlights of product and application segments of the Global Biotechnology Reagents Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company: Here, the competition in the Worldwide Global Biotechnology Reagents Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data: As the name suggests, this section gives the sales data of key players of the Global Biotechnology Reagents Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the Global Biotechnology Reagents Market.

Market Status and Outlook by Region: In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the Global Biotechnology Reagents Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User: This section of the research study shows how different end-user/application segments contribute to the Global Biotechnology Reagents Market.

Market Forecast: Here, the report offers a complete forecast of the Global Biotechnology Reagents Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion: This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Excerpt from:
COVID 19 PANDEMIC: Biotechnology Reagents Market is poised to achieve continuing growth During Forecast Period 2020-2026 - Cole of Duty

A rating of 9 puts Therapix Biosciences Ltd - ADR (TRPX) near the bottom of the Biotechnology industry according to InvestorsObserver. Therapix Biosciences Ltd - ADR's score of 9 means it scores higher than 9% of stocks in the industry. Therapix Biosciences Ltd - ADR also received an overall rating of 22, putting it above 22% of all stocks. Biotechnology is ranked 10 out of the 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 22 would rank higher than 22 percent of all stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Therapix Biosciences Ltd - ADR (TRPX) stock is down -2.31% while the S&P 500 is up 0.05% as of 11:03 AM on Tuesday, May 19. TRPX is lower by -$0.01 from the previous closing price of $0.42 on volume of 654,488 shares. Over the past year the S&P 500 has gained 4.05% while TRPX is lower by -87.27%. TRPX lost -$2.40 per share the over the last 12 months.

To see the top 5 stocks in Biotechnology click here.

Read more:
Where Does Therapix Biosciences Ltd - ADR (TRPX) Stock Fall in the Biotechnology Field? - InvestorsObserver

PHOENIX--(BUSINESS WIRE)-- BioLab, Inc., a regenerative biotechnology company, today announced a partnership with Red One Medical that will help veterans and active military members access breakthrough wound healing and regenerative medicine.

Red One Medical is private sector innovation partner of Department of Veterans Affairs (VA) and Department of Defense (DoD) hospitals. As a Service-Disabled Veteran-Owned Small Business (SDVOSB), it provides advanced medical and pharmaceutical technologies that improve patient care for America's military veterans. BioLab Sciences is working with Red One Medical to distribute regenerative medicine products and MyOwn Skin, a novel biotechnology that can accelerate the healing of severe burns, chronic wounds, diabetic foot ulcers, and other difficult-to-heal wounds.

Nearly one in four veterans has diabetes, and as such, the need for an innovative wound care solution is critical to treat non-healing diabetic ulcersthe leading cause of lower-limb amputations in non-combat veterans.

Were constantly on the lookout for innovative products to speed wound healing in veteran and military hospitals," said Red One Medical CEO and Founder Charles Pollak. "We want our veterans to receive top quality care, and MyOwn Skin takes wound care to the next level by leveraging a patient's own skin to quickly grow skin grafts in a new, non-invasive way."

MyOwn Skin leverages a very small sample of a patient's skin and blood taken through a non-surgical procedure to reproduce three, 100cm2 skin grafts within a week. MyOwn Skin eliminates the need for traditional skin grafts which require surgical procedures to remove large areas of healthy skin from other parts of a patients body, often resulting in additional wounds requiring care and healing time.

We are on a mission to help patients and providers access regenerative medicine products that help the body achieve optimal performance, said BioLab Sciences President and CEO Bob Maguire. As the VAs private sector innovation partner, Red One Medical is in a unique position to help advance the delivery of care to our nations veteran and military patients. This partnership is one step forward in that direction.

Along with MyOwn Skin, which is now one of the most advanced products in Red One Medical's wound care portfolio, the company will also distribute BioLab Sciences amniotic allograft membrane, amniotic liquid allograft and other regenerative products that promote healing for wound, orthopedic, respiratory and ophthalmic care. The products will be available to the DoD and VA health system, which includes more than 9 million veterans at approximately 1,700 facilities.

About BioLab Sciences

BioLab Sciences is a regenerative medicine company focused on creating new ways to heal the body. Headquartered in Scottsdale, Arizona, BioLab Sciences is uncovering better ways to address orthopedic injuries, wound care, pain management, aesthetic medicine, respiratory ailments, cardiovascular indications, ophthalmic issues, and more. BioLab Sciences is transforming wound care through MyOwn Skin, a remarkable biotechnology that leverages a small sample of a patient's own skin from a non-surgical procedure to produce up to three 4-inch x 4-inch skin grafts in a week. Learn more at http://www.biolabsciences.net/.

About Red One Medical

Red One Medical is a private sector innovation partner of Department of Veterans Affairs (VA) medical centers and Department of Defense (DoD) hospitals. Red One Medical identifies and delivers advanced medical and pharmaceutical technologies that transform care for Americas military veterans. Located in Savannah, GA, Red One Medical is a CVE-certified Service Disabled Veteran Owned Business (SDVOSB) and SBA-certified Historically Underutilized Business Zone (HUBZone) company. It donates a portion of profits to charities that support veterans, military families and their communities.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200520005189/en/

See more here:
BioLab Sciences Partners with Red One Medical to Provide Transformative Wound Healing Products to Veterans and Active Military - BioSpace

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the stem cell therapy market and it is poised to grow by USD 588.22 million during 2020-2024, progressing at a CAGR of almost 7% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Please Request Free Sample Report on COVID-19 Impact

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Gilead Sciences Inc., Holostem Terapie Avanzate Srl, Lineage Cell Therapeutics Inc., Lonza Group Ltd., Novartis AG, Nuvasive Inc., Organogenesis Inc., Osiris Therapeutics Inc., RTI Surgical Holdings Inc., and Vericel Corp. are some of the major market participants. The increase in awareness of stem cell therapy will offer immense growth opportunities. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Increase in awareness of stem cell therapy has been instrumental in driving the growth of the market.

Stem Cell Therapy Market 2020-2024: Segmentation

Stem Cell Therapy Market is segmented as below:

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR43432

Stem Cell Therapy Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. Our stem cell therapy market report covers the following areas:

This study identifies limited number of FDA-approved stem cell therapies as one of the prime reasons driving the stem cell therapy market growth during the next few years.

Stem Cell Therapy Market 2020-2024: Vendor Analysis

We provide a detailed analysis of vendors operating in the stem cell therapy market, including some of the vendors such as Gilead Sciences Inc., Holostem Terapie Avanzate Srl, Lineage Cell Therapeutics Inc., Lonza Group Ltd., Novartis AG, Nuvasive Inc., Organogenesis Inc., Osiris Therapeutics Inc., RTI Surgical Holdings Inc., and Vericel Corp. Backed with competitive intelligence and benchmarking, our research reports on the stem cell therapy market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Stem Cell Therapy Market 2020-2024: Key Highlights

Table Of Contents:

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Type

Customer landscape

Geographic Landscape

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

Vendor Analysis

Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

See the article here:
Analysis on Impact of COVID-19-Stem Cell Therapy Market 2020-2024 | Increase in Awareness of Stem Cell Therapy to Boost Growth | Technavio - Business...

DUBLIN, May 13, 2020 /PRNewswire/ -- The "Global Stem Cell Therapy Market By Type (Allogeneic, Autologous, Syngeneic), By Source of Stem Cells (Adipose Tissue, Bone Marrow, Neural, Embryo/Cord Blood derived, iPSCs, Others), By Application, By End Users, By Region, Forecast & Opportunities, 2025" report has been added to ResearchAndMarkets.com's offering.

The Global Stem Cell Therapy Market is expected to grow at a formidable rate of around 12% during the forecast period. The industry is segmented based on type, source of stem cells, application, end-users, company and region.

The market is driven by the growing popularity and awareness pertaining to the use of stem cells for the prevention and cure of certain life threatening diseases. Additionally, increase in number of stem cell banks and growing investments by the government and private organizations for the development of stem cell preservation infrastructure is further propelling the market across the globe.

Based on type, the market can be categorized into allogeneic, autologous and syngeneic. The allogenic type segment is expected to register the highest growth during forecast period attributable to the rising commercialization of allogeneic stem cell therapy products, wider therapeutic applications of allogeneic stem cells, easy production scale-up process, growing number of clinical trials related to allogeneic stem cell therapies, among others.

Based on end-users, the market can be bifurcated into hospitals and clinics. The hospitals segment is expected to dominate the market during the forecast years. This can be accredited to the rising preference for stem cell therapies offered by hospitals proves beneficial for the business growth. Hospitals have affiliations with research laboratories and academic institutes that carry out research activities for developing stem cell therapies. On introduction and approval of any novel stem therapy, hospitals implement it immediately.

Regionally, the stem cell therapy market has been segmented into various regions namely Asia-Pacific, North America, South America, Europe, and Middle East & Africa. Among these regions, North America is expected to dominate the overall stem cell therapy market during the next five years on account of the increasing number of clinical trials for stem cell-based products and increasing public-private funding & research grants.

Major players operating in the Global Stem Cell Therapy Market include Osiris Therapeutics, Inc., MEDIPOST Co., Ltd., Anterogen Co., Ltd., Pharmicell Co., Ltd., Holostem Terapie Avanzate S.r.l., JCR Pharmaceuticals Co., Ltd., NuVasive, Inc., RTI Surgical, Inc., AlloSource, Thermo Fisher Scientific and others. The companies are developing advanced technologies and launching new services in order to stay competitive in the market.

Years considered for this report:

Objective of the Study

Key Topics Covered

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Stem Cell Therapy Market Outlook5.1. Market Size & Forecast5.1.1. By Value5.2. Market Share & Forecast5.2.1. By Type (Allogeneic, Autologous, Syngeneic)5.2.2. By Source of Stem Cells (Adipose Tissue, Bone Marrow, Neural, Embryo/Cord Blood Derived, iPSCs, Others)5.2.3. By Application (Musculoskeletal, Wound & Injury, Cardiovascular Disease (CVD), Surgery, Acute Graft-Versus-Host Disease, Drug Discovery & Development, Others)5.2.4. By End Users (Hospitals v/s Clinics)5.2.5. By Company (2019)5.2.6. By Region5.3. Product Market Map

6. Asia-Pacific Stem Cell Therapy Market Outlook

7. Europe Stem Cell Therapy Market Outlook

8. North America Stem Cell Therapy Market Outlook

9. South America Stem Cell Therapy Market Outlook

10. Middle East and Africa Stem Cell Therapy Market Outlook11. Market Dynamics11.1. Drivers11.2. Challenges

12. Market Trends & Developments

13. Competitive Landscape13.1. Osiris Therapeutics, Inc.13.2. MEDIPOST Co. Ltd.13.3. Anterogen Co. Ltd.13.4. Pharmicell Co. Ltd.13.5. Holostem Terapie Avanzate S.r.l.13.6. JCR Pharmaceuticals Co. Ltd.13.7. NuVasive, Inc.13.8. RTI Surgical, Inc.13.9. AlloSource13.10. Thermo Fisher Scientific

14. Strategic Recommendations

For more information about this report visit https://www.researchandmarkets.com/r/j7namd

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Read more from the original source:
Stem Cell Therapy | Global Industry Review 2015-2019 and Forecast to 2025 - PRNewswire

May 17, 2020 Trial results presented today revealed a promising therapy for patients experiencing angina due to coronary microvascular dysfunction (CMD). The results of the study were presented as feature clinical research during the Society for Cardiovascular Angiography and Interventions (SCAI) 2020 Virtual Conference. CMD is heart disease that causes the small blood vessels feeding the heart muscle to not work as normal. CMD results in ischemia, angina and adverse outcomes in patients with non-obstructive coronary artery disease (NOCAD), with a high predilection for women. Patients experience significant impairment in their quality of life, and no specific therapy for CMD exists.

The authors concluded that CD34+ cell therapy appears to be a promising therapy for CMD patients with angina and NOCAD. A prospective, randomized clinical trial is forthcoming.

This was a proof of concept trial to evaluate the safety and efficacy of CD34+ stem cells administered via intracoronary infusion for CMD patients with abnormal coronary flow reserve of less than 2.5, said Timothy D. Henry, M.D., MSCAI, lead author of the study and SCAI vice president. Our results demonstrate a significant improvement in coronary flow reserve with a single intracoronary infusion of CD34+ cells as well as a significant improvement in angina and quality of life.

CD34+ cell therapy augments microvasculature in preclinical models and improves symptoms, exercise tolerance and mortality in refractory angina obstructive coronary artery disease patients. CD34+ stem cells are a naturally occurring endothelial progenitor cell shown in pre-clinical models to improve microvascular angiogenesis in ischemic tissues. Clinical studies in refractory angina, critical limb ischemia, and dilated cardiomyopathy have shown therapeutic benefit, including reduction in angina, improvement in exercise time, a reduction in amputation and mortality.

Researchers conducted a two-center NHLBI-sponsored (R44HL135889)1 trial of autologous CD34+ cell therapy (CLBS16-P01) (NCT03508609) in 20 NOCAD patients with persistent angina and invasive coronary flow reserve (CFR) 2.5. Measures included angina frequency, CCS Class, Seattle Angina Questionnaire (SAQ), modified Bruce exercise treadmill test (ETT), and labs. Subjects received GCSF 5 mcg/kg/day for 5 days before leukapheresis, followed by manufacturing to select the CD34+ cells.

Cells were administered via a single infusion to the LAD coronary artery. Six-month assessment included invasive CFR, angina frequency, CCS, SAQ and ETT.CFR significantly increased from 2.08+/-0.3 at baseline to 2.68+/-0.8 at 6 months after a single infusion of CD34+ cells (p=0.0045) and study investigators reported that there were no cell-related adverse events.

Find links to the rest of the SCAI late-breaking trials and other SCAI news

See the article here:
Stem Cell Therapy Improved Quality of Life in Patients with Microvascular Dysfunction - Diagnostic and Interventional Cardiology

SAN DIEGO (KGTV) With the search for a coronavirus cure, researchers say unproven stem cell products are being pushed as treatment for COVID-19.

"I think these businesses kind of tap into very vulnerable populations. People who are looking for help, maybe theyre hopeful, maybe theyre desperate," said Leigh Turner, a bioethicist at the University of Minnesota.

Turner has been studying the direct-to-consumer marketing of stem cell therapies and related products for nearly a decade.

His recent paper about "Preying on Public Fears and Anxieties in a Pandemic" recently appeared in the journal Cell Stem Cell. He focused on businesses that were making marketing representations that were not compliant with federal law.

"Theyre not accurate. Theyre not evidence-based," Turner said.

His research said that businesses make vague claims on their websites about stem cell treatments for COVID-19. He mentioned one Southern California anti-aging clinic that used YouTube videos to promote "stem cell exosome" products that were shipped to clients homes.

Turner also wrote about an Arizona regenerative medicine that advertised stem cell therapy as a "precautionary measure" for preventing COVID-19.

"I think its both illegal and unethical," Turner said.

The FDA has sent letters to businesses in several states warning them about their unsubstantiated claims of coronavirus prevention and treatment.

"Do everything you can to avoid being scammed because this is a moment where there are a lot of people out there trying to do helpful things in all kinds of ways, but there are other individuals who see this as an opportunity to make money," Turner said.

View original post here:
Warning about stem cell treatments and COVID-19 - 10News

Home Topics Lung Infection

The Food and Drug Administration (FDA) has approved a phase 1/2a study evaluating the use of umbilical cord mesenchymal stem cells for the treatment of patients with severe cases of coronavirus disease 2019 (COVID-19).

The multicenter, randomized, blinded, placebo-controlled SUCCESS (Systemic Umbilical Cord Cells to Ease Severe Syndrome) study will assess the efficacy and safety of umbilical cord mesenchymal stem cells provided by RESTEM, a cell-based therapeutics company, in hospitalized patients with severe COVID-19 (N=60). RESTEMs cells are grown from umbilical cord tissue through a proprietary process that rapidly replicates millions of doses.

The SUCCESS study will identify COVID-19 patients with acute respiratory distress syndrome (ARDS) who would best benefit from the therapy. Patient enrollment is expected to begin this week from Baptist Health South Florida and Sanford Health.

We are excited to launch this study and demonstrate the potential of our patented umbilical cord lining stem cell (ULSC) technology, said Dr. Rafael Gonzalez, senior vice president of research & development for RESTEM. Based on the properties of our cells and targeted treatments, our breakthrough technology has shown promise to help those suffering from COVID-19 complications.

Use of the novel therapy for COVID-19 was based on promising results in patients previously treated at the Miami Cancer Institute under the FDAs Emergency Use Authorization. Treatment with umbilical cord mesenchymal stem cells was associated with a reduction in both oxygen requirements and circulating inflammatory markers in 3 critically ill COVID-19 patients.

For more information visit sanfordhealth.org or baptisthealth.net.

This article originally appeared on MPR

Please login or register first to view this content.

LoginRegister

Next post in Lung InfectionClose

Read the rest here:
Umbilical Cord Stem Cell Therapy to Be Assessed in Severe COVID-19 - Pulmonology Advisor

THE world's top sports stars are preferring to use stem cell treatment, instead of undergoing major surgery that could leave them out for months.

Cristiano Ronaldo, Rafael Nadal, and most recently Mike Tyson have all tried the therapy, which can cost anywhere from 4,000 to 15,000, when they've suffered injury.

Ailments that can be treated, include tendon inflammation, muscle strain, arthritis, degenerative disc disease, and even bone fractures.

And sportsman who have undergone stem cell therapy are benefitting from improved results, as well as a faster recovery time.

Collected from the blood from a newborn babys umbilical cord, the bone marrow or from body fat, stem cells are injected into an athletes' affected area.

They get to work by replenishing damaged cells from an injury or through wear and tear.

Stem cells also help reduce pain and inflammation, increase blood flow, and promote soft-tissue growth.

It helps the body to heal naturally, and means sports stars can potentially avoid going under the surgeon's knife.

When you're a top sports star, if you get injured the first thing you want to do is get back into the thick of action as quick as possible.

Unfortunately, many injuries can take a long time to heal, and will never allow the sportsman in question to return to the same level he/she was at before the injury.

That's where stem cell treatment is a game-changer.

Forget surgery, steroid injections, and lengthy physiotherapy, which don't always repair the issue at hand.

Stem cell treatments offer an alternative, albeit at a price, to have a non-surgical therapy that's non-evasive and, more importantly, heals the problem fast cutting out the need of rehabilitation.

Better still, some patients have reported that the therapy has not only reversed existing damage, but has strengthened cells against further damage.

Juventus star Ronaldo and Spanish tennis hero Nadal are all fans of stem cell treatment.

Back in 2016, when the Portuguese forward was playing for Real Madrid, he suffered a hamstring tear that threatened to keep him out of action of an important Champions League game against Manchester City.

Although he missed the first leg, he was back for the second - less than three weeks after suffering the problem.

That same year, Ronaldo tore a collateral ligament in his knee during Portugals Euro 2016 final against France.

Again, he turned to stem cell treatment and was back in training with Los Blancos just a month after his knee complaint.

Nadal's chronic knee problems forced him to take seven months off from tennis in 2013.

But stem cell treatment allowed the cartilage to repair. In the seven years since he's won six Grand Slams, there's been no setbacks from his troublesome knee and he appears as mobile as ever.

The Spaniard also cured a long-standing back problem with the therapy.

The former heavyweight champion, who is considering making a comeback, is the latest name to have tried stem cell treatment.

TRAGIC FINDBody found in search for Shad Gaspard 'matches' former WWE star

BETTER KOUL SAULFerdinand urges Man Utd to splash out on Koulibaly, Sancho and Saul Niguez

FAILURE TO LAUNCHMan Utd wonderkids that failed to make the grade from Macheda to Gibson

'YOU CARE'Neil Ruddock gets pacemaker as he thanks Paul Merson for booze intervention

NEW (RONAL)DOGeorgina Rodriguez braids Cristiano Ronaldo's hair for Juventus return

WHITE NOISEUFC chief Dana White launches furious rant calling reporter 'd***head'

EDGE OF YOUR SEATEdge and Randy Orton to have 'greatest wrestling match ever' at Backlash

Video

FAST AS MIKENINGWatch Tyson's speed and power as he vows to fight with the 'spirit of Mao'

It is not known what Tyson, 53, was suffering from - but he was happy to reveal all in an Instagram chat with basketball legend Shaquille O'Neal.

Iron Mike said: "You know what I had done? I had stem-cell research therapy.

"I feel like a different person but I can't comprehend why I feel this way. It's really wild what scientists can do."

Read more:
Tyson, Ronaldo, and more sports stars who use stem cell treatment costing up to 15,000 to speed up healing - The Sun

Iron Mike will break his soul to get back in peak physical condition (Pictures: Instagram / @MikeTyson)

Heavyweight boxing legend Mike Tyson has explained his gruelling training regime as he bids to return to the ring and says he is still feeling weird after using stem-cell therapy.

The 53-year-old showed off his incredible, age-defying speed and power in training footage he uploaded to Instagram last week, declaring he was back and ready to take part in exhibition fights for charity.

Iron Mike has already been inundated with potential challengers to fight, with old heavyweight rival Evander Holyfield posting his own video in response to Tyson and opening the door to a potential third fight between the pair.

Joe Rogan recently suggested that Tysons incredible speed and power was not down to natural hard work alone, and now the veteran boxer has revealed the extreme lengths he is going to in order to get back in shape.

Speaking on the Rock the Bells Radio show on SiriusXM, Tyson was asked by rapper LL Cool J how he would get in peak shape in just six to eight weeks and replied: Really I would just change my diet and just do cardio work. Cardio has to start, you have to have your endurance to go and do the process of training.

So something to do is get in cardio, I would try and get two hours of cardio a day, make sure you get that stuff in. Youre gonna make sure youre eating the right food.

For me its almost like slave food. Doing what you hate to do but doing it like its nothing. Getting up when you dont want to get up. Thats what it is. Its becoming a slave to life.

People think a slave to life is just enjoying drugs and living your life. Being a slave to life means being the best person you can be, being the best you can possibly be, and when you are at the best you can possibly be is when you no longer exist and nobody talks about you. Thats when youre at your best.

Probed further on the mental aspect of preparing for a fight, Tyson continued: My mind wouldnt belong to me. My mind would belong to somebody that disliked me enough to break my soul, and I would give them my mind for that period of time.

Six weeks of this and Id be in the best shape Ive ever dreamed of being in. As a matter of fact, Im going through that process right now. And you know what else I did, I did stem-cell research.

After LL Cool J asked if that meant Tysons white blood cells had been spun and then put back in, Tyson continued: Yes. As they took the blood it was red and when it came back it was almost transfluid [sic], I could almost see through the blood, and then they injected it in me. And Ive been weird ever since, Ive got to get balanced now.

Tyson first revealed that he had undergone stem cell treatment which is usually used to treat or prevent a disease or condition in an Instagram live chat with Shaquille ONeal earlier this month.

You know what I had done? I had stem cell therapy, said Iron Mike. I feel like a different person but I cant comprehend why I feel this way. Its really wild what scientists can do.

MORE: Evander Holyfield demands bizarre no knockouts rule for potential Mike Tyson comeback fight

MORE: Joe Rogan shocked by fu*king sensational training videos of Mike Tyson

Follow Metro Sport across our social channels, on Facebook, Twitter and Instagram.

For more stories like this, check our sport page.

Originally posted here:
Mike Tyson lifts lid on training regime and stem-cell therapy ahead of comeback - Metro.co.uk

Skeletal Disease

The report is a compilation of different studies, including regional analysis where leading regional Musculoskeletal Disorder Stem Cell Therapy markets are comprehensive studied by market experts. Both developed and developing regions and countries are covered in the report for a 360-degree geographic analysis of the Musculoskeletal Disorder Stem Cell Therapy market. The regional analysis section helps readers to become familiar with the growth patterns of important regional Musculoskeletal Disorder Stem Cell Therapy markets. It also provides information on lucrative opportunities available in key regional Musculoskeletal Disorder Stem Cell Therapy markets.

Ask For Discounts, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=226064&utm_source=COD&utm_medium=888

Table of Content

1 Introduction of Musculoskeletal Disorder Stem Cell Therapy Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Musculoskeletal Disorder Stem Cell Therapy Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Musculoskeletal Disorder Stem Cell Therapy Market, By Deployment Model

5.1 Overview

6 Musculoskeletal Disorder Stem Cell Therapy Market, By Solution

6.1 Overview

7 Musculoskeletal Disorder Stem Cell Therapy Market, By Vertical

7.1 Overview

8 Musculoskeletal Disorder Stem Cell Therapy Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Musculoskeletal Disorder Stem Cell Therapy Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Get Complete Report

@ https://www.marketresearchintellect.com/need-customization/?rid=226064&utm_source=COD&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Musculoskeletal Disorder Stem Cell Therapy Market Size, Musculoskeletal Disorder Stem Cell Therapy Market Trends, Musculoskeletal Disorder Stem Cell Therapy Market Growth, Musculoskeletal Disorder Stem Cell Therapy Market Forecast, Musculoskeletal Disorder Stem Cell Therapy Market Analysis Sarkari result, Government Jobs, Sarkari naukri, NMK, Majhi Naukri,

Follow this link:
Musculoskeletal Disorder Stem Cell Therapy Market Development, Trends, Key Driven Factors, Segmentation And Forecast to 2020-2026 - Cole of Duty

Research Organizations

The report is a compilation of different studies, including regional analysis where leading regional Animal Stem Cell Therapy markets are comprehensive studied by market experts. Both developed and developing regions and countries are covered in the report for a 360-degree geographic analysis of the Animal Stem Cell Therapy market. The regional analysis section helps readers to become familiar with the growth patterns of important regional Animal Stem Cell Therapy markets. It also provides information on lucrative opportunities available in key regional Animal Stem Cell Therapy markets.

Ask For Discounts, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=232902&utm_source=COD&utm_medium=888

Table of Content

1 Introduction of Animal Stem Cell Therapy Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Animal Stem Cell Therapy Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Animal Stem Cell Therapy Market, By Deployment Model

5.1 Overview

6 Animal Stem Cell Therapy Market, By Solution

6.1 Overview

7 Animal Stem Cell Therapy Market, By Vertical

7.1 Overview

8 Animal Stem Cell Therapy Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Animal Stem Cell Therapy Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Get Complete Report

@ https://www.marketresearchintellect.com/need-customization/?rid=232902&utm_source=COD&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Animal Stem Cell Therapy Market Size, Animal Stem Cell Therapy Market Trends, Animal Stem Cell Therapy Market Growth, Animal Stem Cell Therapy Market Forecast, Animal Stem Cell Therapy Market Analysis Sarkari result, Government Jobs, Sarkari naukri, NMK, Majhi Naukri,

More here:
Animal Stem Cell Therapy Market Development, Trends, Key Driven Factors, Segmentation And Forecast to 2020-2026 - Cole of Duty

Latest Report On Animal Stem Cell Therapy Market including Market Landscape, and Market size, Revenues by players, Revenues by regions, Average prices, Competitive landscape, market Dynamics and industry trends and developments during the forecast period.

The global Animal Stem Cell Therapy market is broadly analyzed in this report that sheds light on critical aspects such as the vendor landscape, competitive strategies, market dynamics, and regional analysis. The report helps readers to clearly understand the current and future status of the global Animal Stem Cell Therapy market. The research study comes out as a compilation of useful guidelines for players to secure a position of strength in the global market. The authors of the report profile leading companies of the global Animal Stem Cell Therapy market, Also the details about important activities of leading players in the competitive landscape.

Key companies operating in the global Animal Stem Cell Therapy market include: Medivet Biologics LLC, VETSTEM BIOPHARMA, J-ARM, U.S. Stem Cell, Inc, VetCell Therapeutics, Celavet Inc., Magellan Stem Cells, Kintaro Cells Power, Animal Stem Care, Animal Cell Therapies, Cell Therapy Sciences, Animacel

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1090738/global-animal-stem-cell-therapy-market

The report predicts the size of the global Animal Stem Cell Therapy market in terms of value and volume for the forecast period 2020-2026. As per the analysis provided in the report, the global Animal Stem Cell Therapy market is expected to rise at a CAGR of xx % between 2020 and 2026 to reach a valuation of US$ xx million/billion by the end of 2026. In 2020, the global Animal Stem Cell Therapy market attained a valuation of US$ XX million/billion. The market researchers deeply analyze the global Animal Stem Cell Therapy industry landscape and the future prospects it is anticipated to create

Segmental Analysis

The report has classified the global Animal Stem Cell Therapy industry into segments including product type and application. Every segment is evaluated based on growth rate and share. Besides, the analysts have studied the potential regions that may prove rewarding for the Animal Stem Cell Therapy manufcaturers in the coming years. The regional analysis includes reliable predictions on value and volume, thereby helping market players to gain deep insights into the overall Animal Stem Cell Therapy industry.

Global Animal Stem Cell Therapy Market Segment By Type:

Dogs, Horses, Others

Global Animal Stem Cell Therapy Market Segment By Application:

Veterinary Hospitals, Research Organizations

Competitive Landscape

It is important for every market participant to be familiar with the competitive scenario in the global Animal Stem Cell Therapy industry. In order to fulfil the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.

Key companies operating in the global Animal Stem Cell Therapy market include: Medivet Biologics LLC, VETSTEM BIOPHARMA, J-ARM, U.S. Stem Cell, Inc, VetCell Therapeutics, Celavet Inc., Magellan Stem Cells, Kintaro Cells Power, Animal Stem Care, Animal Cell Therapies, Cell Therapy Sciences, Animacel

Key questions answered in the report:

Get Full Report in your inbox within 24 hours at USD(3350):

https://www.qyresearch.com/settlement/pre/5126b8b50ef1c7215e7a58e48d22665a,0,1,global-animal-stem-cell-therapy-market

TOC

Table of Contents 1 Animal Stem Cell Therapy Market Overview1.1 Animal Stem Cell Therapy Product Overview1.2 Animal Stem Cell Therapy Market Segment by Type1.2.1 Dogs1.2.2 Horses1.2.3 Others1.3 Global Animal Stem Cell Therapy Market Size by Type1.3.1 Global Animal Stem Cell Therapy Sales and Growth by Type1.3.2 Global Animal Stem Cell Therapy Sales and Market Share by Type (2014-2019)1.3.3 Global Animal Stem Cell Therapy Revenue and Market Share by Type (2014-2019)1.3.4 Global Animal Stem Cell Therapy Price by Type (2014-2019) 2 Global Animal Stem Cell Therapy Market Competition by Company2.1 Global Animal Stem Cell Therapy Sales and Market Share by Company (2014-2019)2.2 Global Animal Stem Cell Therapy Revenue and Share by Company (2014-2019)2.3 Global Animal Stem Cell Therapy Price by Company (2014-2019)2.4 Global Top Players Animal Stem Cell Therapy Manufacturing Base Distribution, Sales Area, Product Types2.5 Animal Stem Cell Therapy Market Competitive Situation and Trends2.5.1 Animal Stem Cell Therapy Market Concentration Rate2.5.2 Global Animal Stem Cell Therapy Market Share of Top 5 and Top 10 Players2.5.3 Mergers & Acquisitions, Expansion 3 Animal Stem Cell Therapy Company Profiles and Sales Data3.1 Medivet Biologics LLC3.1.1 Company Basic Information, Manufacturing Base and Competitors3.1.2 Animal Stem Cell Therapy Product Category, Application and Specification3.1.3 Medivet Biologics LLC Animal Stem Cell Therapy Sales, Revenue, Price and Gross Margin(2014-2019)3.1.4 Main Business Overview3.2 VETSTEM BIOPHARMA3.2.1 Company Basic Information, Manufacturing Base and Competitors3.2.2 Animal Stem Cell Therapy Product Category, Application and Specification3.2.3 VETSTEM BIOPHARMA Animal Stem Cell Therapy Sales, Revenue, Price and Gross Margin(2014-2019)3.2.4 Main Business Overview3.3 J-ARM3.3.1 Company Basic Information, Manufacturing Base and Competitors3.3.2 Animal Stem Cell Therapy Product Category, Application and Specification3.3.3 J-ARM Animal Stem Cell Therapy Sales, Revenue, Price and Gross Margin(2014-2019)3.3.4 Main Business Overview3.4 U.S. Stem Cell, Inc3.4.1 Company Basic Information, Manufacturing Base and Competitors3.4.2 Animal Stem Cell Therapy Product Category, Application and Specification3.4.3 U.S. Stem Cell, Inc Animal Stem Cell Therapy Sales, Revenue, Price and Gross Margin(2014-2019)3.4.4 Main Business Overview3.5 VetCell Therapeutics3.5.1 Company Basic Information, Manufacturing Base and Competitors3.5.2 Animal Stem Cell Therapy Product Category, Application and Specification3.5.3 VetCell Therapeutics Animal Stem Cell Therapy Sales, Revenue, Price and Gross Margin(2014-2019)3.5.4 Main Business Overview3.6 Celavet Inc.3.6.1 Company Basic Information, Manufacturing Base and Competitors3.6.2 Animal Stem Cell Therapy Product Category, Application and Specification3.6.3 Celavet Inc. Animal Stem Cell Therapy Sales, Revenue, Price and Gross Margin(2014-2019)3.6.4 Main Business Overview3.7 Magellan Stem Cells3.7.1 Company Basic Information, Manufacturing Base and Competitors3.7.2 Animal Stem Cell Therapy Product Category, Application and Specification3.7.3 Magellan Stem Cells Animal Stem Cell Therapy Sales, Revenue, Price and Gross Margin(2014-2019)3.7.4 Main Business Overview3.8 Kintaro Cells Power3.8.1 Company Basic Information, Manufacturing Base and Competitors3.8.2 Animal Stem Cell Therapy Product Category, Application and Specification3.8.3 Kintaro Cells Power Animal Stem Cell Therapy Sales, Revenue, Price and Gross Margin(2014-2019)3.8.4 Main Business Overview3.9 Animal Stem Care3.9.1 Company Basic Information, Manufacturing Base and Competitors3.9.2 Animal Stem Cell Therapy Product Category, Application and Specification3.9.3 Animal Stem Care Animal Stem Cell Therapy Sales, Revenue, Price and Gross Margin(2014-2019)3.9.4 Main Business Overview3.10 Animal Cell Therapies3.10.1 Company Basic Information, Manufacturing Base and Competitors3.10.2 Animal Stem Cell Therapy Product Category, Application and Specification3.10.3 Animal Cell Therapies Animal Stem Cell Therapy Sales, Revenue, Price and Gross Margin(2014-2019)3.10.4 Main Business Overview3.11 Cell Therapy Sciences3.12 Animacel 4 Animal Stem Cell Therapy Market Status and Outlook by Regions4.1 Global Market Status and Outlook by Regions4.1.1 Global Animal Stem Cell Therapy Market Size and CAGR by Regions4.1.2 North America4.1.3 Asia-Pacific4.1.4 Europe4.1.5 South America4.1.6 Middle East and Africa4.2 Global Animal Stem Cell Therapy Sales and Revenue by Regions4.2.1 Global Animal Stem Cell Therapy Sales and Market Share by Regions (2014-2019)4.2.2 Global Animal Stem Cell Therapy Revenue and Market Share by Regions (2014-2019)4.2.3 Global Animal Stem Cell Therapy Sales, Revenue, Price and Gross Margin (2014-2019)4.3 North America Animal Stem Cell Therapy Sales, Revenue, Price and Gross Margin4.3.1 United States4.3.2 Canada4.3.3 Mexico4.4 Europe Animal Stem Cell Therapy Sales, Revenue, Price and Gross Margin4.4.1 Germany4.4.2 UK4.4.3 France4.4.4 Italy4.4.5 Russia4.4.6 Turkey4.5 Asia-Pacific Animal Stem Cell Therapy Sales, Revenue, Price and Gross Margin4.5.1 China4.5.2 Japan4.5.3 Korea4.5.4 Southeast Asia4.5.4.1 Indonesia4.5.4.2 Thailand4.5.4.3 Malaysia4.5.4.4 Philippines4.5.4.5 Vietnam4.5.5 India4.5.6 Australia4.6 South America Animal Stem Cell Therapy Sales, Revenue, Price and Gross Margin4.6.1 Brazil4.7 Middle East and Africa Animal Stem Cell Therapy Sales, Revenue, Price and Gross Margin4.7.1 Egypt4.7.2 GCC Countries 5 Animal Stem Cell Therapy Application/End Users5.1 Animal Stem Cell Therapy Segment by Application5.1.1 Veterinary Hospitals5.1.2 Research Organizations5.2 Global Animal Stem Cell Therapy Product Segment by Application5.2.1 Global Animal Stem Cell Therapy Sales by Application5.2.2 Global Animal Stem Cell Therapy Sales and Market Share by Application (2014-2019) 6 Global Animal Stem Cell Therapy Market Forecast6.1 Global Animal Stem Cell Therapy Sales, Revenue Forecast (2019-2025)6.1.1 Global Animal Stem Cell Therapy Sales and Growth Rate Forecast (2019-2025)6.1.1 Global Animal Stem Cell Therapy Revenue and Growth Rate Forecast (2019-2025)6.2 Global Animal Stem Cell Therapy Forecast by Regions6.2.1 North America Animal Stem Cell Therapy Sales and Revenue Forecast (2019-2025)6.2.2 Europe Animal Stem Cell Therapy Sales and Revenue Forecast (2019-2025)6.2.3 Asia-Pacific Animal Stem Cell Therapy Sales and Revenue Forecast (2019-2025)6.2.3.1 China6.2.3.2 Japan6.2.3.3 Korea6.2.3.4 Southeast Asia6.2.3.5 India6.2.3.6 Australia6.2.4 South America Animal Stem Cell Therapy Sales and Revenue Forecast (2019-2025)6.2.5 Middle East and Africa Animal Stem Cell Therapy Sales and Revenue Forecast (2019-2025)6.2.5.1 Egypt6.2.5.2 GCC Countries6.3 Animal Stem Cell Therapy Forecast by Type6.3.1 Global Animal Stem Cell Therapy Sales and Revenue Forecast by Type (2019-2025)6.3.2 Dogs Gowth Forecast6.3.3 Horses Gowth Forecast6.4 Animal Stem Cell Therapy Forecast by Application6.4.1 Global Animal Stem Cell Therapy Sales Forecast by Application (2019-2025)6.4.2 Global Animal Stem Cell Therapy Forecast in Veterinary Hospitals6.4.3 Global Animal Stem Cell Therapy Forecast in Research Organizations 7 Animal Stem Cell Therapy Upstream Raw Materials7.1 Animal Stem Cell Therapy Key Raw Materials7.1.1 Key Raw Materials7.1.2 Key Raw Materials Price7.1.3 Raw Materials Key Suppliers7.2 Manufacturing Cost Structure7.2.1 Raw Materials7.2.2 Labor Cost7.2.3 Manufacturing Expenses7.3 Animal Stem Cell Therapy Industrial Chain Analysis 8 Marketing Strategy Analysis, Distributors8.1 Marketing Channel8.1.1 Direct Marketing8.1.2 Indirect Marketing8.1.3 Marketing Channel Development Trend8.2 Distributors8.3 Downstream Customers 9 Research Findings and Conclusion AppendixMethodology/Research ApproachResearch Programs/DesignMarket Size EstimationMarket Breakdown and Data TriangulationData SourceSecondary SourcesPrimary SourcesDisclaimer

About Us

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Read the original:
Animal Stem Cell Therapy Market Outlook, Regional Analysis, key Drivers and Restraints, by Product, Top Players and Forecast Analysis 2020-2026 -...

Emirati dentist with the officials Image Credit: Supplied

Ras Al Khaimah: An Emirati dentist, who received stem cell therapy after she got infected with coronavirus (COVID-19) due to transmission from a patient, was recently visited by Dr Mohamed Salim Al Olama, undersecretary of the Ministry of Health and Prevention (MoHAP) and head of the Board of Directors of the Emirates Health Services Corporation.

Dr Muhra Abdul Rahim Al-Awadi, who underwent the innovative stem cell therapy, is one of the current patients at Obaidullah Elderly Hospital in Ras Al Khaimah.

Dr Al Olama also made a series of field visits to determine the readiness of various hospitals and the conditions of medical cadres across the country, according to MoHAP.

He expressed his appreciation to Al-Awadis diligence and dedication to her homeland and called it as a national example of giving, loyalty, and sacrifice.

He added MoHAP is proud of its medical sector and it pays great attention to its employees health through the provision of the best methods of infection prevention.

According to MoHAP, Al-Awadi thanked Dr Al Olama for the visit, which pleased and motivated her to continue to work diligently after her full recovery.

She said at present she does not have any symptoms of fever or breathing difficulty and that she is recuperating after receiving stem cell therapy.

See the original post:
Coronavirus: Emirati dentist who received stem cell therapy doing well - Gulf News

Medical science has proven time and again that when the resources are provided, great progress in the treatment, cure, and prevention of disease can occur. - Michael J Fox

It makes sense right now to have exposure to biotech stocks, especially companies working on COVID-19 treatments. Over the past six months, the returns on biotech stocks have been much higher than the broader market indices, as attempts to contain coronavirus are on the rise. The WHO predicts there are approximately 70 vaccines in development worldwide, with experts expecting it to take between 12 and 18 months before approval of a vaccine for mass use. Apart from companies working on vaccines, many companies are developing treatments for conditions related to COVID-19, including Acute Respiratory Distress Syndrome (ARDS). Pluristem Therapeutics (PSTI) is one of the companies which received significant financing to work on COVID-19 and ARDS-related treatments.

Pluristem Therapeutics is an Israeli company. It signed a 50 million financing agreement with the European Investment Bank to develop therapies related to COVID-19 in April. This agreement comes one month after PSTI announced its use of patented PLX cells in severely ill COVID-19 patients suffering from ARDS achieved positive results. ARDS is the condition, brought on by COVID-19, which causes severe, often fatal, lung damage. Stem cell therapy treatments hope to treat and reverse the overreaction of the immune system caused by ARDS. The ICU patients, which were on respirators, all survived. Some of the patients saw the regeneration of lung tissue after hospitalization. One additional patient has received treatment in New Jersey. This news led PSTI's price to triple from approximately $3.00/share throughout April to approximately $9.00/share in May.

Twenty-eight days after this announcement, of the eight patients studied, there is an 87.5% survival rate of the patients treated with the PLX cells, with 75% of them being off mechanical ventilation and 62.5% discharged alive from the hospital. This rate compares to 3.3% of patients suffering from ARDS discharged alive from the hospital in the New York area from March-April 2020 after being on ventilation. While this is a small sample, these numbers are promising as PSTI moves forward with Phase II clinical trials in the United States.

The company uses stem cells derived from placentas, which are easy to collect and accepted as ethical in parts of the world that reject other kinds of stem cells. In the past month, PSTI increased by 206.2%, significantly outperforming the sector as a whole and making noise in the biotech field.

In general, stem cell therapy shows promise in treating ARDS. Fellow Seeking Alpha contributor Wall Street Titan discussed five stem cell companies moving quickly toward an ARDS therapy. This contributor's article discusses many of the positives and negatives of the five companies, including PSTI. The article is worth a read, but the main argument the author has against PSTI is that its scalability lags behind the other companies. I see this as more of a long-term issue, not an issue that would impact its value in the short term. In the meantime, it has outperformed three of the five stem cell companies working on ARDS therapy over the past six months.

I am relatively bullish on this stock in the short term. The FDA cleared PSTI's application for a Phase II study of its ARDS treatment, with 140 adults, intubated, and mechanically ventilated patients receiving various injections and dosages of the PLX-PAD cells. The number of ventilator-free days will measure efficacy during the twenty-eight days from day one to twenty-eight of the study. At least one investment bank is betting that, despite the company producing no revenue, continued positive news from the company is bound to increase the stock price. There may be truth to this. The company which outperformed PSTI over the past six months - Capricor Therapeutics (CAPR) - saw its shares spike April 28 after positive news about its product (100% survival rate for six patients). For now, it seems good news means big spikes in the share price.

However, I will not say this company does not have its share of risk over the long term.

First, when looking at biotech companies, one of the main factors is whether it has a history of approved drugs. Pluristem does not have any approved drugs yet, but it does have several treatments in its pipeline. Before the COVID-19 outbreak, it had two PLacental eXpanded (PLX) products that had reached phase 3 clinical trials in the U.S., Europe, and Israel. These products treat Critical Limb Ischemia (an obstruction of arteries decreasing blood flow to the extremities, causing pain and ulcers) and muscle regeneration following hip fracture.

Further, Pluristem received an orphan drug designation from the FDA to treat Acute Radiation syndrome, which will potentially accelerate this therapy's path to approval and other benefits. The company was also cleared by the U.S. government to treat victims exposed to high doses of radiation due to a nuclear attack or accident. It is also in phase 1 or 2 for treatments involving intermittent claudication, graft versus host disease, and bone marrow transplant treatments. So, in the absence of any approved products, it's nice to see that there are at least several clinical studies underway and near completion.

Second, the company's books are not in great shape. According to its March 2020 10-Q filing, its revenue was $22,000 over the prior nine months, compared to a net loss of $21,016,000, amounting to a loss per share of $1.28. This net loss is slightly less from the nine months ending 2019, which was $27,547,000. Its primary source of funds has been the sale of common stock and government grants. It is eligible for grants from Israel's Law for the Encouragement of Industrial Research and Development and has received almost $28 million from these grants. It also receives numerous grants from the Israel Ministry of Economy and Industry and some private grants. Between April 1 and May 7, the company sold 4.3 million shares of common stock. These funds are in addition to the non-dilutive finance contract from the European Investment Bank, which will be paid in tranches when the company reaches certain milestones.

Third, there is always the chance that ARDS treatments are developed more quickly by different companies. However, I am slightly optimistic Pluristem could maintain a place in the recovery even if a different company produces a similar cell therapy before them. For instance, PSTI uses intramuscular administration (injection into the muscle), instead of intravenous (injection into the vein). Some studies show that intramuscular administration is preferable. I am not a doctor, but there is a possibility that different variations of these treatments will serve different purposes.

In the short term, I believe this stock has the momentum to be a good buy, especially with good news likely coming on the horizon. Trading volume exploded in April, with it remaining strong in comparison to its price. While there is a risk to this stock, if your portfolio can handle it, it may be a good buy. If Pluristem ends up being one of the major players in solving this crisis, it may end up being one of the better bargains you can find during this period.

Like this article? Don't forget to hit the Follow button

Sometimes, you might not realize your biggest portfolio risks until it's too late.

That's why it's important to pay attention to the right market data, analysis, and insights on a daily basis. Being a passive investor puts you at unnecessary risk. When you stay informed on key signals and indicators, you'll take control of your financial future.

My award-winning market research gives you everything you need to know each day, so you can be ready to act when it matters most.

Click here to gain access and try the Lead-Lag Report FREE for 14 days.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: This writing is for informational purposes only and Lead-Lag Publishing, LLC undertakes no obligation to update this article even if the opinions expressed change. It does not constitute an offer to sell, a solicitation to buy, or a recommendation regarding any securities transaction. It also does not offer to provide advisory or other services in any jurisdiction. The information contained in this writing should not be construed as financial or investment advice on any subject matter. Lead-Lag Publishing, LLC expressly disclaims all liability in respect to actions taken based on any or all of the information on this writing.

Go here to see the original:
Pluristem Therapeutics: The Search For An ARDS Treatment, And Whether Its Growth Will Continue - Seeking Alpha

Travelers the world over are asking: Where can I travel that's safe?

Sha Wellness Clinic, a medical clinic and hotel in southeastern Spain, has an answer. It's requiring guests to provide a negative Covid-19 test result before they ever step foot in the door.

"When we began to put together our preventative measures, there was no doubt that this would be a requirement," said Alejandro Bataller, vice president of the clinic. "Our main priority is ensuring our guests' safety while at Sha, so they can have peace of mind during their stay."

Covid-19 and antibody tests are free of charge to guests at Sha Wellness Clinic.

Courtesy of Sha Wellness Clinic

The medicalclinic, which is located in Alicante, Spain, is banking on the fact that requiring guests to get a coronavirus test before they arrive is the very thing that will make guests want to come.

"During these times, people are more concerned than ever about their safety when it comes to traveling," Bataller said. "Guests can have some peace of mind knowing that everyone visiting has been tested, and the spaces are constantly being sanitized, so they can truly relax and feel confident and safe."

All guests must undergo Covid-19 testing 24 to 48 hours before arriving at Sha Wellness Clinic. Guests are encouraged to send the results, though Sha will allow them to bring the results when they arrive too.

Guests are not the only ones being tested. The clinic staff is required to get tested for Covid-19 before returning to work and regularly thereafter.

Upon arrival, all guests will undergo a second Covid-19 test as well as an antibody test and a medical examination. All testing is included with a stay free of charge.

"It is important to us that our guests not only feel safe when returning to Sha, but also feel healthier during their stay," said Bataller.

In line with post-pandemic changes happening across the hotel industry, the clinic is intensifying its cleaning protocol, installing thermographic cameras to detect body temperatures and eliminating all paper touch points, such as food and spa menus.

Sha Wellness Clinic is located in Alicante, Spain.

Courtesy of Sha Wellness Clinic

UV disinfection towers will be installed in the clinic suites, and ozone treatments will be used to disinfect vehicles and luggage. The check-in process is being moved into guest suites.

As part of all stays, guests embark on health programs that focus on topics like fitness, detoxing and weight loss. The clinic has 11 residences where guests can undergo treatments and medical consultations without having to leave their suites.

The clinic is reducing occupancy levels in common areas to encourage social distancing.

Courtesy of Sha Wellness Clinic

Sha is adding to its immune system treatments in response to the pandemic and adding new "immune system strengthening" services. Guests can undergo stem cell therapy, infrared heat, vitamin C megadoses, thermal shock reinforcement and stress management sessions, to name a few. Immunotherapy and lymphocyte profile consultations are now included in all bookings as well.

A seven-day booking for the "rebalance" program in late July in the entry-level deluxe suite is approximately 5,310 euros (US$5,745). To upgrade to a bi-level garden residence, the rate jumps to 17,000 euros (US$18,390) and nearly twice that figure for a stay in the penthouse residence.

The Waldhotel, a medical wellness resort in Obbrgen, Switzerland, is testing guests for Covid-19, though it does not require a negative test result before guests can check in.

Tests cost 150 Swiss francs (US$154) and are administered in the Waldhotel Health & Medical Excellence, a medical center that operates in the hotel.

"Although the Waldhotel Health & Medical Excellence remained open throughout the pandemic, no Covid-19 case has been registered in the Waldhotel and the Brgenstock Resort," said Dr. Verena Briner, the medical director of the center, referencing the larger resort in which the Waldhotel resides.

The Waldhotel is part of the Brgenstock Hotels & Resort, near Switzerland's Lake Lucerne.

Courtesy of Waldhotel

The Waldhotel has Covid-19 antibody testing for guests for 100 Swiss francs (US$102) with results returned in one day.

As the Waldhotel is a five-star hotel and medical center in one, the hotel says it had strict hygiene measures in place such as hand disinfection stations and housekeeping protocols before the pandemic started. Still, it instituted new measures in response to the virus under the guidance of Dr. Briner.

The Waldhotel Health & Medical Excellence center operates inside the Waldhotel.

Courtesy of Waldhotel

The medical center employs a team of experts in dermatology, gastroenterology, sports medicine and dentistry. Hotel guests can join guided programs that focus on exercise, aesthetics, mindfulness, immunity and weight loss. Programs range from three days to two weeks, though some guests stay for months.

The hotel has access to an airfield where private jets can land for guests who can afford to avoid commercial airlines.

International travel to Spain and Switzerland isn't possible right now, but it may soon be, depending on where you live.

After two of months of strict lockdown, Spain began to lift nationwide stay-at-home guidelines in May. Currently, Spain has a 14-day quarantine requirement for most people arriving from abroad, though Spain's Transport Minister Jose Luis Abalos said he hopes tourism activity will start again in late June.

The lobby of the Waldhotel.

Courtesy of Waldhotel

Sha Wellness Clinic closed at the end of March and is aiming to reopen in July, pursuant to guidelines set forth by the Spanish government.

Right now, only Swiss citizens, residents and select workers can enter Switzerland. However, Switzerland announced intentions to broadly reopen its borders with Germany, Austria and France on June 15. There are no plans to reopen borders with Italy yet.

On May 14, Swiss International Air Lines announced it would restart flying up to 190 flights from Zurich and Geneva in June. Flights will resume in stages and will go to 41 European destinations including Paris, Rome, Barcelona and Copenhagen. Additionally, the airline is providing new intercontinental direct connections in June, linking Zurich to New York, Singapore, Tokyo and Johannesburg, among other cities.

Continue reading here:
Hotel in Spain requires two negative Covid-19 tests to check in with a free antibody test during your stay - CNBC

BUFFALO, N.Y. For decades, the enormous disease-curing potential of human stem cells has been thwarted by the inability to produce sufficient quantities of mature human cells in vivo in a living organism.

Now, a team led by University at Buffalo scientists has developed a method that dramatically ramps up production of mature human cells in mouse embryos. Producing human cells in vivo is critical because cells made in a petri dish often do not behave the same way that cells do in the body.

The research was published on May 13 in Science Advances.

This is fundamental research that allows us to use the mouse embryo to help us better understand human development, said Jian Feng, PhD, corresponding author and professor of physiology and biophysics in the Jacobs School of Medicine and Biomedical Sciences at UB.

Further development of our technology could enable the generation of even larger quantities of specific types of mature human cells to allow us to create more effective mouse models to study diseases that gravely affect humans, such as malaria or COVID-19, said Feng.

And because this method produces so many mature human cells, it could potentially generate materials to treat chronic diseases, such as diabetes or kidney failure, by replacing a patients damaged cells with healthy human cells or tissues.

Infectious disease applications

Feng explained that it might be possible to create a much better mouse model of the human immune system or components of the human respiratory system in order to study COVID-19, a disease that wreaks havoc in humans, but barely affects mice.

It could also be possible to use the new method to produce mice with even more mature human red blood cells. Such mice would be very effective in the study of malaria, a disease which affects only humans by destroying our red blood cells.

We have a lot of questions to answer before the technology can be useful, but this is the first time that anyone has generated so many mature human cells in a mouse embryo, said Feng.

Millions of mature human cells in 17 days

Previous efforts to produce human cells in mouse embryos have generated small amounts of immature cells that are hard to quantify. In contrast, the UB method resulted in millions of mature human cells in a mouse embryo in 17 days.

In this study, the researchers injected 10-12 nave human stem cells into a mouse blastocyst when it was 3.5 days old. The mouse embryo then generated millions of mature human cells, including red blood cells, eye cells and liver cells, as it developed.

We know that up to four percent of the total number of cells in the mouse embryo were human cells, Feng. This is a low estimate because we cannot quantify the large amount of human red blood cells generated in the mouse embryo.

He said that because these mature human red blood cells do not have a nucleus, they are not counted by the method that the scientists use to quantify the total number of cells.

The teams technique involved overcoming an important challenge: Converting human pluripotent stem cells, which can differentiate into all types of cells in the body, into a form that is compatible with the inner cell mass inside a mouse blastocyst a three-day old mouse embryo. The human stem cells are in a primed state, whereas the inner cell mass inside the mouse blastocyst is in a nave state.

When the primed human cells are put into the mouse blastocyst, they fail to develop, said Feng, noting that the mismatch between the cells different developmental stages seems to be responsible.

We wanted to see if it was possible for the human primed cells to go back to the nave state, just like the pluripotent stem cells inside a mouse blastocyst, said Feng. This is what we have done.

Our method is to transiently inhibit the mTOR kinase for three hours to shock the human primed cells to the nave state, said Feng. Blocking the mTOR kinase triggers a series of events that rewire gene expression and cellular metabolism so that the primed cells become nave.

Converting the later stage human primed stem cells back to an earlier, less developed nave state allowed the human stem cells to co-develop with the inner cell mass in a mouse blastocyst.

The injected human stem cells now develop at the much more rapid pace of the mouse embryo, supporting the generation of millions of mature human cells in 17 days, said Feng.

In addition to Feng, UB co-authors are Zhixing Hu, Hanqin Li, Houbo Jiang, Yong Ren, and Boyang Zhang of the Department of Physiology and Biophysics, and Xinyang Yu and Michael J. Buck of the Department of Biochemistry, all of the Jacobs School. Other co-authors are Jingxin Qiu and Aimee B. Stablewski of the Roswell Park Comprehensive Cancer Center.

Funding for this research was provided by NYSTEM and the Buffalo Blue Sky Initiative.

Go here to see the original:
Scientists generate millions of mature human cells, far more than have ever been produced - UB News Center

Scientists have placed more mature human cells in mouse embryos. The progress is expected to help the medical community improve the development of treatments, including those for COVID-19.

Over the past decades, scientists faced challenges in producing enough amounts of human cells in animals. It is important to grow human cells in other living organisms in the lab since cells made in a petri dish commonly do not behave like those in the body, Futurity reported.

This is fundamental research that allows us to use the mouse embryo to help us better understand human development, Jian Feng, corresponding study author and a professor in the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo, said in a statement.

He added that the study, described in the journal Science Advances, marks the first time that so many mature human cells were generated in a mouse embryo. The new approach provided millions of mature human cells and took only 17 days to produce such amounts in the lab.

Researchers tested the approach with a mouse blastocyst, a three-day-old embryo. It involved injecting human stem cells into the animal and converting the cells to become compatible with the inner cell mass inside a mouse embryo.

Putting the human stem cells into the naive state allowed them to co-develop with the cells in the mouse. The process then helped the embryo produce millions of mature human cells, including red blood cells, eye cells and liver cells.

Feng said having higher amounts of human cells may help improve how scientists understand human development and disease. It provides a better mouse model to study health conditions, such as diabetes, kidney failure and even COVID-19.

Further development of our technology could enable the generation of even larger quantities of specific types of mature human cells to allow us to create more effective mouse models to study diseases that gravely affect humans, the researcher said.

Improving the approach may also eventually allow scientists to produce more mature human red blood cells in mice. That would help explore health problems and disease that mainly affect red blood cells.

Scientists at the University at Buffalo used a new method that helped them produce millions of mature human cells in a mouse embryo, a progress that may help improve study of common diseases, like diabetes, malaria and COVID-19. Pixabay

Read this article:
Heres The Reason Why Scientists Are Growing Human Cells In Mouse Embryo - Medical Daily

SILVER SPRING, Md., May 20, 2020 /PRNewswire/ -- You have probably heard of GMOs or genetically modified organisms, but how much do you know about them? GMO is a common term used by consumers to describe foods that have been created through genetic engineering. While GMOs have been available to consumers since the early 1990s and are a common part of today's food supply, research shows consumers have limited knowledge and understanding about what GMOs are, why they are used, and how they are made.

The U.S. Food and Drug Administration (FDA), with the U.S. Department of Agriculture (USDA) and U.S. Environmental Protection Agency (EPA), launched Feed Your Mind, a new Agricultural Biotechnology Education and Outreach Initiative. The Initiative aims to increase consumer awareness and understanding of genetically engineered foods or GMOs.Find answers to your questions and help educate others with Feed Your Mind's science-based educational resources, like web pages, fact sheets, infographics, and videos.

What are GMOs?"GMO" is a common term used to describe a plant, animal, or microorganism that has had its DNA changed through a process scientists call genetic engineering. Most of the GMO crops grown today were developed to help farmers prevent crop loss. There are ten GMO cropscurrently grown and sold in the U.S.: alfalfa, apples, corn, cotton, papayas, potatoes, soybeans, summer squash, and sugar beets.

Are GMOs safe to eat?Many federal agencies play an important role in ensuring the safety of GMOs. FDA, USDA, and EPA work together to ensure that crops produced through genetic engineering are safe for people, animals, and the environment. Collaboration and coordination among these agencies help make sure food developers understand the importance of a safe food supply and the rules they need to follow when creating new plants through genetic engineering.

Look for "Bioengineered food" on food labels Soon, you may see the term "bioengineered food" on certain food packaging. Congress used "bioengineered food" to describe certain types of GMOs when it passed the National Bioengineered Food Disclosure Standard. The Standard establishes requirements for labeling foods people eat that are bioengineered or may have bioengineered ingredients. It also defines bioengineered foods as those that contain detectable genetic material that has been modified through certain lab techniques and cannot be created through conventional breeding or found in nature.

To learn more about the Feed Your MindInitiative, visit http://www.fda.gov/feedyourmind.

Contact: Media: 1-301-796-4540 Consumers: 1-888-SAFEFOOD (toll free)

Go here to see the original:
Feed Your Mind with FDA's New Education Initiative on Genetically Engineered Foods - Herald-Mail Media